摘要
HER2阳性乳腺癌约占所有乳腺癌的15%~20%,其侵袭性强且预后较差。曲妥珠单抗的应用显著改善了患者的预后,但仍有部分患者会出现曲妥珠单抗耐药。本文报道一例应用"伊尼妥单抗"联合"吡咯替尼"及"艾立布林"后疗效显著的曲妥珠单抗原发耐药的晚期乳腺癌患者。
Approximately 15%~20% of patients with metastatic breast cancer have HER2-positive disease,which isassociated with more aggressive disease biology and historically,a poorer prognosis relative to other molecular subtypes. The application of trastuzumab has greatly improved patients outcomes,however,trastuzumab-resistance is common. We presented a HER-2 positive metastatic breast cancer case,who was diagnosed as primary trastuzumab resistance and successfully treated with inetetamab combined with pyrotinib and eribulin.
作者
桂秀娟
赵健丽
汪颖
柴洁
丁林潇潇
姚和瑞
GUI Xiu-juan;ZHAO Jian-li;WANG Ying;CHAI Jie;DIN Lin-xiao-xiao;YAO He-rui(Breast TumorCenter,Sun Yat-senMemorialHospital,Sun Yat-senUniversity,Guangzhou 510120,China)
出处
《岭南现代临床外科》
2021年第6期675-678,共4页
Lingnan Modern Clinics in Surgery
基金
国家自然科学基金(82071754)。
作者简介
通讯作者:姚和瑞,Email:yaoherui@mail.sysu.edu.cn。
